Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Promacta Effective In Raising Platelet Count In HCV-Associated Thrombocytopenia, Phase II Data Show

This article was originally published in The Pink Sheet Daily

Executive Summary

Results published in the New England Journal of Medicine demonstrate 95 percent of hepatitis C patients with thrombocytopenia taking 75 mg dose of eltrombopag once daily had elevated platelet counts.

You may also be interested in...



GSK Battles Back With Strong 2Q Results, Says 2012 Will Be A Transformational Year

After hitting a low point, GlaxoSmithKline believes its second quarter results reflect a turnaround for the company and the progress the company has made in strengthening it portfolio.

GSK Battles Back With Strong 2Q Results, Says 2012 Will Be A Transformational Year

After hitting a low point, GlaxoSmithKline believes its second quarter results reflect a turnaround for the company and the progress the company has made in strengthening it portfolio.

GSK Files Promacta NDA For Short-Term Treatment Of ITP

If approved, drug will be first oral platelet growth factor for idiopathic thrombocytopenic purpura.

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel